The therapeutic management of differentiated thyroid cancer.
BACKGROUND
The management of thyroid cancer is difficult because the tumors comprise a wide range of biologic behaviors, from small papillary thyroid microcarcinomas that pose little or no threat to survival for the patient, to anaplastic thyroid cancers that are arguably the most lethal tumor. Although it may be difficult initially to determine at which end of the prognostic spectrum a patient resides, one can ordinarily estimate a patient's risk for tumor recurrence and mortality based on a triad of features as simple as the patient's age at the time of diagnosis, the tumor stage at presentation, and its initial response to therapy. While staging systems are available to assist in the management process, all are inexact and leave wide gaps in the treatment plan for a given patient. This is largely because randomized controlled trials are lacking as a result of the low incidence and generally favorable prognosis of the disease. As a practical matter, it may sometimes be difficult to reassure a patient, given the generally favorable prognosis of this group of tumors, knowing that without adequate therapy some become unexpectedly aggressive and recur years after initial management. The treatment of these tumors rests on a fine balance of providing care that reflects the anticipated course of the disease without overtreating the patient or providing reassurance that is unfounded.


OBJECTIVE
To outline the treatment strategy for patients with differentiated thyroid cancer based on the available literature and to guide clinicians through a management algorithm utilizing patient and tumor characteristics.


METHODS
This review is limited to the treatment of patients with differentiated thyroid cancer - papillary and follicular thyroid cancer - and the standard therapy required for the majority of patients.


CONCLUSIONS
The treatment of differentiated thyroid cancer requires a multidisciplinary approach, involving an experienced surgeon, radiologists and an endocrinologist. There are many unanswered questions in the management algorithm and ongoing research is needed to further define the best treatment strategy for patients with differentiated thyroid cancer.
Sipos
Jennifer A
JA
University of Florida, 1600 Archer Road, PO Box 100226, Gainesville, FL 32610, USA. jennifer.sipos@medicine.ufl.edu
Mazzaferri
Ernest L
EL
D002454:Cell Differentiation; D003131:Combined Modality Therapy; D020249:Hormone Replacement Therapy; D006801:Humans; D008197:Lymph Node Excision; D011183:Postoperative Complications; D011859:Radiography; D011879:Radiotherapy Dosage; D013963:Thyroid Hormones / Q000008:administration & dosage; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D013965:Thyroidectomy; D013972:Thyrotropin / Q000037:antagonists & inhibitors
D013963:Thyroid Hormones; D013972:Thyrotropin